Dr. Gallia Levy is the Chief Medical Officer at Spark Therapeutics with responsibility for setting the global development strategy.
Gallia was previously VP and Global Head of the Rare Blood Disorders Franchise at Genentech/Roche, where she was responsible for the clinical development of treatments for hemophilia A and other rare blood disorders. Gallia first joined Genentech in 2009, working in both early and late-stage clinical development. She later moved to Portola Pharmaceuticals, where she led the registrational program for ANDEXXA®. She returned to Genentech in 2014, to lead the global clinical development program for HEMLIBRA® from Phase 1 to global registration for adults and children with hemophilia A.
Gallia is board-certified in hematology and earned an M.D. and Ph.D. in Molecular and Cellular Biology from the University of Michigan, during which time she discovered ADAMTS13, responsible for Thrombotic Thrombocytopenic Purpura.
She completed her residency in internal medicine at Stanford University and fellowship in hematology at the University of California, San Francisco. She also has worked at the Pasteur Institute, where she received an M.S. in Molecular and Cellular Biology from the University of Paris, VI and holds a B.A. in Molecular and Cell Biology from the University of California, Berkeley.